Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, EMEA To Improve Collaboration On Risk Management

Executive Summary

A new implementation plan for the confidential information sharing arrangement between FDA, the European Medicines Agency and the European Commission will place an emphasis on collaboration to streamline pharmacovigilance requirements

You may also be interested in...



Pharmacovigilance Is A Global Safety Issue – DIA Singapore Conference

Pharmacovigilance and risk management is a global safety issue, and the quality of safety data that is being retrieved is more important than where the data is coming from, according to consultant and former U.S. FDA MedWatch Medical Director Stephen Goldman

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
UsernamePublicRestriction

Register

PS048303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel